Hydrocortisone Bristol Laboratories

Hydrocortisone Bristol Laboratories is an oral medication that contains the glucocorticoid hydrocortisone. It is marketed in the European Union without a listed strength or specific dosage form. Classified under ATC code H02AB02, the product is intended for oral administration to replace deficient cortisol and to reduce inflammation in various clinical situations, and should be used under the guidance of a healthcare professional before starting therapy according to.

Hydrocortisone Bristol Laboratories is prescribed for conditions where cortisol replacement or anti‑inflammatory action is required.

- Primary adrenal insufficiency (Addison’s disease) to replace endogenous cortisol. - Congenital adrenal hyperplasia requiring glucocorticoid supplementation. - Acute or chronic inflammatory disorders such as rheumatoid arthritis, ulcerative colitis, or severe dermatitis. - Management of allergic reactions, including severe skin or airway inflammation. - Supportive therapy during stress or surgery for patients with known adrenal insufficiency. - Treatment of adrenal crisis when rapid cortisol replacement is needed. - Adjunctive therapy in certain endocrine disorders such as pituitary insufficiency.

Like other systemic glucocorticoids, oral hydrocortisone may cause a range of adverse reactions, which vary in frequency and severity.

Common: - Increased appetite or weight gain. - Mild gastrointestinal discomfort such as nausea or dyspepsia. - Fluid retention leading to mild peripheral edema. - Mood changes including irritability or mild anxiety. - Elevated blood glucose levels, especially in patients with diabetes.

Serious: - Severe infection due to immunosuppression. - Significant hypertension or worsening of pre‑existing cardiovascular disease. - Osteoporosis or pathological fractures with long‑term use. - Adrenal suppression causing crisis on abrupt discontinuation. - Psychiatric disturbances such as psychosis or severe depression.

When prescribing oral hydrocortisone, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use.

- Assess baseline adrenal function and consider stress dosing during illness or surgery. - Monitor blood pressure, glucose, and electrolyte levels regularly. - Use the lowest effective dose for the shortest duration possible. - Evaluate for a history of peptic ulcer disease or gastrointestinal bleeding. - Screen for osteoporosis risk, especially in long‑term therapy. - Caution in patients with uncontrolled infections or active tuberculosis. - Avoid use during pregnancy unless benefits outweigh potential risks.

Oral hydrocortisone can interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid: - Concurrent use of strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce hydrocortisone plasma levels. - High‑dose non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase the risk of gastrointestinal bleeding.

Use with caution: - Anticoagulants (e.g., warfarin) because glucocorticoids may enhance anticoagulant effects. - Antidiabetic agents, as hydrocortisone can raise blood glucose and require dose adjustments. - Vaccines, particularly live attenuated vaccines, due to possible immunosuppression. - Diuretics, which may exacerbate electrolyte disturbances. - Antihypertensive agents, because fluid retention may diminish their efficacy.